J. Erickson

5.1k total citations · 3 hit papers
38 papers, 3.8k citations indexed

About

J. Erickson is a scholar working on Immunology, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, J. Erickson has authored 38 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 15 papers in Pharmacology and 12 papers in Experimental and Cognitive Psychology. Recurrent topics in J. Erickson's work include Psoriasis: Treatment and Pathogenesis (15 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Treatment of Major Depression (11 papers). J. Erickson is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (12 papers) and Treatment of Major Depression (11 papers). J. Erickson collaborates with scholars based in United States, Canada and France. J. Erickson's co-authors include Eduardo Dunayevich, Susan Ball, Dennis Dong Hwan Kim, Frank L. Greenway, Maria Guttadauria, Ken Fujioka, Gregory S. Cameron, Raymond A Plodkowski, Sunder Mudaliar and Daniel Braun and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

J. Erickson

37 papers receiving 3.7k citations

Hit Papers

Effect of naltrexone plus bupropion on weight loss in ove... 2010 2026 2015 2020 2010 2015 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    2010 706 citations Frank L. Greenway, Ken Fujioka et al. The Lancet profile →
  2. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    2015 658 citations C.E.M. Griffiths, Kristian Reich et al. The Lancet profile →
  3. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Erickson United States 24 1.6k 1.4k 1.0k 973 685 38 3.8k
Paul M. Copeland United States 25 147 0.1× 191 0.1× 686 0.7× 131 0.1× 761 1.1× 51 2.7k
Thoralf Wendt Germany 21 528 0.3× 165 0.1× 640 0.6× 29 0.0× 1.4k 2.1× 33 4.8k
Stephen Wright United Kingdom 30 196 0.1× 2.7k 1.8× 226 0.2× 14 0.0× 290 0.4× 67 4.5k
Assumpta Caixàs Spain 31 181 0.1× 158 0.1× 688 0.7× 46 0.0× 783 1.1× 149 2.8k
Mansoureh Togha Iran 30 103 0.1× 241 0.2× 686 0.7× 82 0.1× 85 0.1× 155 3.1k
Wolfgang Köpcke Germany 28 56 0.0× 182 0.1× 198 0.2× 75 0.1× 195 0.3× 65 2.4k
Michael Morcos Germany 18 251 0.2× 99 0.1× 406 0.4× 24 0.0× 531 0.8× 41 2.5k
Arlene J. Morales United States 30 474 0.3× 214 0.1× 340 0.3× 19 0.0× 1.5k 2.2× 52 4.4k
André T. Guay United States 38 45 0.0× 909 0.6× 204 0.2× 54 0.1× 3.6k 5.3× 85 5.0k
Richard V. Clark United States 32 35 0.0× 439 0.3× 704 0.7× 75 0.1× 2.5k 3.6× 63 4.1k

Countries citing papers authored by J. Erickson

Since Specialization
Citations

This map shows the geographic impact of J. Erickson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Erickson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Erickson more than expected).

Fields of papers citing papers by J. Erickson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Erickson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Erickson. The network helps show where J. Erickson may publish in the future.

Co-authorship network of co-authors of J. Erickson

This figure shows the co-authorship network connecting the top 25 collaborators of J. Erickson. A scholar is included among the top collaborators of J. Erickson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Erickson. J. Erickson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guenther, Lyn, Alison Potts Bleakman, Jamie Weisman, et al.. (2019). Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Acta Dermato Venereologica. 100(1). 1–9. 21 indexed citations
2.
Helliwell, P, Éric Lespessailles, Catherine L Shuler, et al.. (2018). Ixekizumab Provides Sustained Improvement In Signs And Symptoms In Patients With Active Psoriatic Arthritis: Two Year Results From A Phase 3 Trial. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 1 indexed citations
3.
Gottlieb, Alice B., Kim Papp, C. Birbara, et al.. (2018). Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. Journal of the American Academy of Dermatology. 79(3). 593–595. 5 indexed citations
4.
Papp, Kim, C. Leonardi, Andrew Blauvelt, et al.. (2017). Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology. 178(3). 674–681. 77 indexed citations
5.
Papp, Kim, Andrew Blauvelt, Neil J. Korman, et al.. (2016). 058 Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3. Journal of Investigative Dermatology. 136(9). S170–S170. 6 indexed citations
6.
Gottlieb, Alice B., Sascha Gerdes, J.‐P. Lacour, et al.. (2016). 052 Efficacy of ixekizumab in moderate-to-severe psoriasis patients who have or have not received prior biologic therapies: An integrated analysis of 3 phase 3 studies. Journal of Investigative Dermatology. 136(9). S169–S169. 5 indexed citations
7.
Gordon, Kenneth B., Andrew Blauvelt, Kim Papp, et al.. (2016). Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine. 375(4). 345–356. 650 indexed citations breakdown →
8.
Kerkhof, P.C.M. van de, Lyn Guenther, A.B. Gottlieb, et al.. (2016). Ixekizumab treatment improves fingernail psoriasis in patients with moderate‐to‐severe psoriasis: results from the randomized, controlled and open‐label phases of UNCOVER‐3. Journal of the European Academy of Dermatology and Venereology. 31(3). 477–482. 60 indexed citations
9.
Griffiths, C.E.M., Kristian Reich, Mark Lebwohl, et al.. (2015). Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 386(9993). 541–551. 658 indexed citations breakdown →
10.
Genovese, Mark C., Daniel Braun, J. Erickson, et al.. (2015). Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis. The Journal of Rheumatology. 43(2). 289–297. 30 indexed citations
11.
Gordon, Kenneth B., Craig L. Leonardi, Mark Lebwohl, et al.. (2014). A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology. 71(6). 1176–1182. 87 indexed citations
12.
Greenway, Frank L., Ken Fujioka, Raymond A Plodkowski, et al.. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 376(9741). 595–605. 706 indexed citations breakdown →
13.
Wadden, Thomas A., John P. Foreyt, Gary D. Foster, et al.. (2010). Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial. Obesity. 19(1). 110–120. 398 indexed citations
14.
Davidson, Jonathan, Christer Allgulander, Mark H. Pollack, et al.. (2008). Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double‐blind, placebo‐controlled studies. Human Psychopharmacology Clinical and Experimental. 23(6). 519–526. 36 indexed citations
15.
Davidson, Jonathan, Hans‐Ulrich Wïttchen, Pierre‐Michel Llorca, et al.. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. European Neuropsychopharmacology. 18(9). 673–681. 52 indexed citations
16.
Hartford, James T., Jean Endicott, Susan G. Kornstein, et al.. (2008). Implications of Pain in Generalized Anxiety Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. 10(3). 197–204. 19 indexed citations
17.
Rynn, Moira A., James Russell, J. Erickson, et al.. (2007). Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and Anxiety. 25(3). 182–189. 112 indexed citations
18.
Russell, James M., Risa B. Weisberg, Maurizio Fava, et al.. (2007). Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depression and Anxiety. 25(7). E1–E11. 30 indexed citations
19.
Hartford, James T., Susan G. Kornstein, Michael R. Liebowitz, et al.. (2007). Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. International Clinical Psychopharmacology. 22(3). 167–174. 99 indexed citations
20.
Dunayevich, Eduardo, J. Erickson, Louise R. Levine, et al.. (2007). Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder. Neuropsychopharmacology. 33(7). 1603–1610. 147 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul M. Copeland Breakdown of academic impact, for papers by Thoralf Wendt Breakdown of academic impact, for papers by Stephen Wright Breakdown of academic impact, for papers by Assumpta Caixàs Breakdown of academic impact, for papers by Mansoureh Togha Breakdown of academic impact, for papers by Wolfgang Köpcke Breakdown of academic impact, for papers by Michael Morcos Breakdown of academic impact, for papers by Arlene J. Morales Breakdown of academic impact, for papers by André T. Guay Breakdown of academic impact, for papers by Richard V. Clark
Rankless by CCL
2026